Preclinical Efficacy Data of Apogenix’ HERA-CD27L Published in Frontiers in Oncology
HERA-CD27L Enhances T Cell Activation and Induces Anti-Tumor Immunity
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in the current volume of Frontiers in Oncology1 demonstrate the potent anti-tumor efficacy of Apogenix’ HERA-CD27L. In contrast to antibodies in development, HERA-CD27L is the first true CD27 receptor agonist with a well-defined mode of action that acts directly on immune cells, thereby enhancing their anti-tumor immunity.